Skip to main content

Semaglutide vs. Tirzepatide: How Do They Differ?

By ElliotMeds · Updated November 4, 2026 · 3 min read

Short answer: semaglutide and tirzepatide are both once-weekly injectable medications used in weight management and type 2 diabetes. Semaglutide activates one hormone receptor (GLP-1). Tirzepatide activates two (GIP and GLP-1). Which one, if either, is appropriate is a decision for a licensed clinician.

This article is educational and is not medical advice. Whether any treatment is appropriate for you is decided by a licensed clinician after reviewing your health history.

What is semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. The FDA-approved semaglutide products are Wegovy (chronic weight management and cardiovascular-risk reduction in certain adults), Ozempic (type 2 diabetes), and Rybelsus (an oral tablet for type 2 diabetes). See MedlinePlus: semaglutide injection.

What is tirzepatide?

Tirzepatide is a dual agonist that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. The FDA-approved tirzepatide products are Zepbound (chronic weight management) and Mounjaro (type 2 diabetes). See MedlinePlus: tirzepatide injection.

How do they compare side by side?

SemaglutideTirzepatide
Receptors targetedGLP-1GIP and GLP-1
FDA-approved brandsWegovy, Ozempic, RybelsusZepbound, Mounjaro
How it's given (approved injectables)Once-weekly injectionOnce-weekly injection
Dosing approachStarts low, increased graduallyStarts low, increased gradually
Main weight-management trial programSTEPSURMOUNT
Common side effectsNausea, vomiting, diarrhea, constipation, abdominal painNausea, vomiting, diarrhea, constipation, abdominal pain, reduced appetite
Boxed warningThyroid C-cell tumors (rodent studies)Thyroid C-cell tumors (rodent studies)

What does the research cover?

Both medications have been studied in large randomized trials published in the New England Journal of Medicine:

  • STEP 1 (2021) studied once-weekly semaglutide in adults with overweight or obesity. Wilding et al., NEJM
  • SELECT (2023) studied semaglutide and cardiovascular outcomes in adults with obesity and without diabetes. Lincoff et al., NEJM
  • SURMOUNT-1 (2022) studied once-weekly tirzepatide for the treatment of obesity. Jastreboff et al., NEJM
  • SURMOUNT-5 (2025) compared tirzepatide with semaglutide directly in adults with obesity. Aronne et al., NEJM

These trials studied the FDA-approved medications. Compounded versions have not been separately studied or FDA-reviewed, and trial results do not carry over to them.

Which one is right for me?

Neither is presented here as better. The two differ in mechanism and side-effect profile, and the right choice — or whether either is appropriate — depends on your health history, other medications, and goals. At ElliotMeds, a licensed U.S. clinician reviews your full intake and makes that decision.

Who should not take either?

Both are not recommended for people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), for people with type 1 diabetes, or during pregnancy. See Who should not take a GLP-1 for the full list.

Learn more

Sources

Every program includes a clinician chart review. When prescribed, treatments are filled by a licensed U.S. pharmacy.

Important note

Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing. A licensed clinician determines whether a treatment is appropriate based on the information provided.